PAMA

PAMA Unlocks Golden Age for Innovative Diagnostics

By Chance Scott  bio The publication of the 2018 Clinical Laboratory Fee Schedule (CLFS) in January saw a long and heated debate within the lab community come to fruition. When Congress … [Read more...]

GENOMICS

Market Trends: Genetic Testing Becoming a Hot New Employee Benefit

While its clinical utility remains subject to debate, genetic testing has proven its value as an employment recruitment tool, especially on the West Coast where technology firms are leveraging its … [Read more...]

MARKET TRENDS

By the Numbers: Spike in M.D. Practice Acquisitions Drives Up Costs of Hospital Care

Hospitals are gobbling up M.D. practices at a record rate. In addition to endangering the independent physician practice, this trend is driving up the costs of hospital care by adding ever higher … [Read more...]

SAFETY

Diagnostic danger in the lab: Time to reform how we process orders

By Oleg Bess, M.D.  bio I don't know about you, but I was stunned by the findings from a recent report published by Coverys, a national liability insurer, which I feel should put the entire … [Read more...]

MARKETING

Theranos & Its CEO Settle Stock Fraud Charges with SEC

Seven years ago, Theranos was a $9 billion dynamo seemingly on the precipice of blowing the blood testing market wide open. Today, the company and its CEO and founder, Elizabeth Holmes, are a … [Read more...]

COVERAGE

Emerging Tests: Medicare to Cover Next Gen-Sequencing Tests for Advanced Cancer

In the PAMA era, there are two salient trends in Medicare Part B lab reimbursements: Sharply lower prices for traditional tests; and Wider coverage of newly emerging tests, including some that … [Read more...]

ANNUAL SURVEY

Outreach Survey Focuses on Clinical Laboratory Industry Trends Amidst Greatest Disruption in Three Decades

By Jeff Myers  bio Accumen Inc. is pleased to announce the launch of the 17th Annual National Hospital and Health System Laboratory and Outreach Survey. The survey is designed to capture … [Read more...]

FEE SCHEDULES

Industry Buzz: ACLA Goes for Kill in PAMA Lab Fees Challenge Case

Attorneys for the American Clinical Laboratory Association asked the federal court for summary judgment in its lawsuit challenging the legality of the new PAMA-based Medicare Part B fee schedule for … [Read more...]

RESEARCH

The Year in Dx VC Investment: Dx/Tools Outperforms Health Care & Liquid Biopsy/AI/ Informatics Outperforms Dx/Tools

In a year that witnessed venture capital health care investment reaching an all-time high, diagnostics/tools (Dx/Tools) companies made out particularly well, according to Silicon Valley Banks' … [Read more...]

INSIDE THE LAB INDUSTRY

PAMA-geddon: Lab Industry Asks Court to Stop New Medicare Fee Schedule

With CMS refusing to back down, the lab industry has escalated the dispute and asked a U.S. District Court to step in and prevent enforcement of the 2018 PAMA-inspired Part B Clinical Lab Fee Schedule … [Read more...]


(-0000g2)